Compile Data Set for Download or QSAR
Report error Found 177 Enz. Inhib. hit(s) with Target = 'Histone acetyltransferase KAT6B'
TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM662989(Synthesis of N-(5-((1H-pyrazol-1-yl)methyl)-3,4-di...)
Affinity DataIC50: 0.700nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM662985(Synthesis of 7-chloro-1-(2-chlorophenyl)-4-(prop-2...)
Affinity DataIC50: 1.10nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM662990(Synthesis of N-(5-((1H-pyrazol-1-yl)methyl)-3,4-di...)
Affinity DataIC50: 1.40nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM739492(N-(4-((1H-pyrazol-1-yl)methyl)-2,2-difluoro-[1,3]d...)
Affinity DataIC50: 1.5nMMore data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
9/9/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534100(WO2022081807, Example 207)
Affinity DataIC50: 5.65nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534020(WO2022081807, Example 127 | 6-(Azetidin-1-yl)-N-(5...)
Affinity DataIC50: 5.67nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534117(WO2022081807, Example 224)
Affinity DataIC50: 9.82nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534118(WO2022081807, Example 225 | 6-(Azetidin-1-yl)-N-[(...)
Affinity DataIC50: 9.82nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534006(WO2022081807, Example 113 | N-(5-tert-butyl-2-etho...)
Affinity DataIC50: 12nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534121(WO2022081807, Example 228)
Affinity DataIC50: 13nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM533972(WO2022081807, Example 79 | 6-(Azetidin-1-yl)-4-flu...)
Affinity DataIC50: 14nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534021(WO2022081807, Example 128)
Affinity DataIC50: 15nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534106(WO2022081807, Example 213)
Affinity DataIC50: 15nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534149(WO2022081842, Example 24)
Affinity DataIC50: 19nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534023(WO2022081807, Example 130)
Affinity DataIC50: 20nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534045(WO2022081807, Example 152)
Affinity DataIC50: 20nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534088(WO2022081807, Example 195)
Affinity DataIC50: 20nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534107(WO2022081807, Example 214 | 6-(azetidin-1-yl)-N-[2...)
Affinity DataIC50: 20nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM533866(WO2022081807, Example 1 | 6-(Azetidin-1 -yl)-N-(2-...)
Affinity DataIC50: 21nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534024(WO2022081807, Example 131 | 6-(Azetidin-1-yl)-N-[2...)
Affinity DataIC50: 23nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534146(WO2022081842, Example 22 | 6-Cyclopropyl-4-fluoro-...)
Affinity DataIC50: 23nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM730788(US20250122182, Example 45, WO2020/254946)
Affinity DataIC50: 24nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM663033(Synthesis of N-(6-((1H-pyrazol-1-yl)methyl)-4-(flu...)
Affinity DataIC50: 25.5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM50518832(CHEMBL4455897 | US10829446, Compound 36)
Affinity DataIC50: 28nMAssay Description:Inhibition of N-terminal GST-tagged recombinant human KAT6B (431 to end residues) expressed in baculovirus infected Sf9 insect cells using acetyl coe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM50518832(CHEMBL4455897 | US10829446, Compound 36)
Affinity DataIC50: 28nMAssay Description:Inhibition of KAT6B (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534122(WO2022081807, Example 229 | 6-(Azetidin-1-yl)-N-[(...)
Affinity DataIC50: 28nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534150(WO2022081842, Example 25 | 6-Cyclopropyl-N-(2-etho...)
Affinity DataIC50: 28nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534124(WO2022081807, Example 231 | 6-(Azetidin-1-yl)-N-((...)
Affinity DataIC50: 29nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM580748(US11492346, Example 90 | US20250122182, Example 98...)
Affinity DataIC50: 40nMMore data for this Ligand-Target Pair
Ligand InfoPDBSimilars
In Depth
Date in BDB:
8/18/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534187(WO2022081842, Example 60 | N-[(2-(Benzyloxy)-5-(te...)
Affinity DataIC50: 45nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534022(WO2022081807, Example 129 | 6-(Azetidin-1-yl)-4-fl...)
Affinity DataIC50: 52nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534145(WO2022081842, Example 21 | 4,6-Dimethyl-N-(2-methy...)
Affinity DataIC50: 53nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653594(US11911372, Example 15 | US20240277683, Example 15)
Affinity DataIC50: 85.4nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653594(US11911372, Example 15 | US20240277683, Example 15)
Affinity DataIC50: 85.4nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM533867(WO2022081807, Example 2 | 6-(Azetidin-1-yl)-N-(2-e...)
Affinity DataIC50: 95nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534140(WO2022081842, Example 16 | N-([1,1'-biphenyl]-2-su...)
Affinity DataIC50: 104nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534131(WO2022081842, Example 7)
Affinity DataIC50: 114nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653651(US11911372, Example 73 | US20240277683, Example 73)
Affinity DataIC50: 117nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653651(US11911372, Example 73 | US20240277683, Example 73)
Affinity DataIC50: 117nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653593(US11911372, Example 14 | US20240277683, Example 14)
Affinity DataIC50: 123nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653593(US11911372, Example 14 | US20240277683, Example 14)
Affinity DataIC50: 123nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM662998(Synthesis of 2,6-dimethoxy-N-(4-(pyridin-2-yloxy)-...)
Affinity DataIC50: 144nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2025
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534148(WO2022081842, Example 23 | N-([1,1'-biphenyl]-2-su...)
Affinity DataIC50: 155nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534133(WO2022081842, Example 9)
Affinity DataIC50: 220nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534130(WO2022081842, Example 6 | 4,6-Dimethyl-N-(2'-methy...)
Affinity DataIC50: 245nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534019(WO2022081807, Example 126)
Affinity DataIC50: 285nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM533902(WO2022081807, Example 26 | 6-(Azetidin-1-yl)-N-([1...)
Affinity DataIC50: 292nMAssay Description:Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-FR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081807

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM534135(WO2022081842, Example 11 | N-(3'-chloro[1,1'-biphe...)
Affinity DataIC50: 299nMAssay Description: Kat6b inhibitory activities of the compounds described in the present invention were quantified using a Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081842

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653595(US11911372, Example 16 | US20240277683, Example 16)
Affinity DataIC50: 310nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetHistone acetyltransferase KAT6B(Human)
Jiangsu Hengrui Pharmaceuticals

US Patent
LigandPNGBDBM653595(US11911372, Example 16 | US20240277683, Example 16)
Affinity DataIC50: 310nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 177 total ) | Next | Last >>
Jump to: